Skip to main content
Loading

Epion Therapeutics, Inc.

Tuesday, February 27, 2024
Plymouth
Ophthalmology
Epion Therapeutics is developing a minimally invasive treatment for keratoconus that can bring early intervention to millions of patients globally. Our EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without mechanical or chemical disruption of the epithelium, allowing for a rapid return to normal activities. Our Phase 2 clinical study completed the enrollment of 2,258 patients. The study showed that EpiSmart-treated keratoconus patients showed statistically significant improvements in best- corrected distance vision at 6 and 12 months post-treatment. Of the patients with keratoconus who were followed for 12 months, over 80% had stable or improved vision following EpiSmart treatment. Epion launched its Phase 3 studies in the fall of 2023. Last year, we announced raising a $32 million Series A funding round led by AXA IM Global Health plus a syndicate of individual investors, including leading cornea specialists.
Speakers
Michael Webb, CEO - Epion Therapeutics, Inc.

State

Massachusetts

Country

United States

Website

http://epiontx.com

CEO/Top Company Official

Michael D. Webb

Lead Product in Development

EpiSmart

Development Phase of Primary Product

Phase III

Number Of Unlicensed Products

One
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Media Partner


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP